Dutch rare dis­ease biotech Pro­QR carves out new com­pa­ny ded­i­cat­ed to epi­der­mol­y­sis bul­losa

Nine months af­ter kick­start­ing hu­man test­ing for its ex­on skip­ping drug for a rare skin dis­or­der called dy­s­troph­ic epi­der­mol­y­sis bul­losa, Dutch biotech Pro­QR Ther­a­peu­tics is spin­ning off the pro­gram in­to a new com­pa­ny — Wings Ther­a­peu­tics — formed and fi­nanced by a non­prof­it found­ed by a group of par­ents, in­clud­ing Pearl Jam’s Ed­die Ved­der.

The on­go­ing Phase I/II study is test­ing the drug — QR-313 — in pa­tients with re­ces­sive dy­s­troph­ic epi­der­mol­y­sis bul­losa (DEB), a se­vere form of an in­her­it­ed skin blis­ter­ing dis­ease that is char­ac­ter­ized by frag­ile skin, chron­ic pain and a high risk of in­fec­tion and mal­nu­tri­tion.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER